Results 141 to 150 of about 1,689,649 (265)
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Hybrid Protective Sentinel System: A Combined Technique for Safe and Controlled Open-Wedge High Tibial Osteotomy. [PDF]
Elazab A +5 more
europepmc +1 more source
Gold testimonial to Capt. Ludlow [picture].
Plate on p. 45 of: Australian picture pleasure book /Walter G.
Mason, Walter G.
core
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Machine learning-driven image encryption using SVM for enhanced security and computational efficiency. [PDF]
Inam S +3 more
europepmc +1 more source
Government House, Sydney, New South Wales [picture].
Plate on p. 1 of: Australian picture pleasure book /Walter G.
Mason, Walter G.
core
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Mixed Localized and Delocalized Bonding in a Linear‑B<sub>3</sub>‑Centered B<sub>3</sub>Mg<sub>6</sub> <sup>-</sup> Cluster. [PDF]
Gao SJ +5 more
europepmc +1 more source
View of dam at Cook's River [picture] /
A plate on p. [5] of: Australian picture pleasure book /Walter G.
Mason, Walter G.
core
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source

